# Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis

## TL;DR

This study shows abrocitinib, a JAK1 inhibitor, may be effective and safe for treating chronic actinic dermatitis, with potential key inflammatory factors identified.

## Contribution

The study provides new clinical insights into abrocitinib's efficacy for chronic actinic dermatitis and identifies specific inflammatory pathways involved.

## Key findings

- Abrocitinib significantly reduced disease severity in 16 CAD patients over 12 weeks.
- Key inflammatory factors like IL-13 and CCL-4 were significantly altered after treatment.
- No serious adverse events were observed during the treatment period.

## Abstract

JAK inhibitors are well-established for their utilization in the treatment of autoinflammatory diseases, with the JAK1 inhibitor abrocitinib primarily employed in the management of atopic dermatitis. To provide new clinical therapeutic experience for patients with chronic actinic dermatitis (CAD), reveal the inflammatory pathways that may be involved in the treatment of CAD with abrocitinib and to provide clues for exploring the pathogenesis of CAD.

In a 3-month longitudinal study, we recorded and analyzed laboratory test data and clinical severity assessments in 16 patients diagnosed with chronic actinic dermatitis treated with abrocitinib. And the plasma samples of 6 patients before and after treatment were analyzed proteomically using Olink inflammation panel.

After 12 weeks of treatment, there was a significant decrease in disease severity scores of 16 patients. No serious adverse events were identified throughout the course of treatment. Significant changes in several inflammatory factors such as EN-RAGE, MCP-3, MCP-4, IL-13, CCL4, FGF21 and TNFRSF9 were observed after treatment.

The analysis of our data demonstrates that abrocitinib may be an effective therapeutic option in the management of CAD. IL-13 and CCL-4 might be the core effective factors after the therapy.